Sharps Technology Files DEFA14A Proxy Statement

TL;DR

Sharps Tech filed proxy docs, no fee. Standard procedure.

AI Summary

Sharps Technology Inc. filed a Definitive Additional Materials proxy statement (DEFA14A) on July 3, 2024. This filing indicates that no fee was required for this filing. The company is incorporated in Nevada and its fiscal year ends on December 31.

Why It Matters

This filing is a routine regulatory submission for Sharps Technology Inc., providing updated proxy materials to shareholders. It doesn't contain new strategic information but is a necessary step in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new material information that would typically impact stock price or indicate significant risk.

Key Players & Entities

• Sharps Technology Inc. (company) — Registrant
• 20240703 (date) — Filing Date
• NV (state) — State of Incorporation
• 1231 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value STSS NASDAQ Capital Marke

Filing Documents

• formdefa41a.htm (DEFA14A) — 66KB
• 0001493152-24-026149.txt ( ) — 67KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 3, 2024 SHARPS TECHNOLOGY, INC. /s/ Robert Hayes Robert Hayes Chief Executive Officer Exhibit 99.1 Sharps Technology Urges Shareholders to Approve the Proposals in connection with the Special Meeting on July 15, 2024 All shareholders of record as of May 17, 2024 are eligible to vote Final votes must be cast by 11:59 p.m., Eastern Time on July 12, 2024 NEW YORK, July 3, 2024 – Sharps Technology, Inc. (NASDAQ: “ STSS ” and “STSSW’ ) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, encourages its shareholders to participate actively in the upcoming special meeting of stockholders to be held on July 15, 2024 at 10:00 a.m. eastern time. The Board of Directors emphasizes the importance of this shareholders’ vote, specifically so that the C ompany can achieve its goal of passing the three proposals as listed and explained in the Company’s definitive proxy statement filed on June 26, 2024. The Company encourages you to vote, even if you no longer own the shares but were a shareholder of record on the record date of May 17, 2024. Failure to secure the requisite number of votes to achieve the Company’s goal of passing these three proposals may materially impair the Company from executing essential business matters and may limit the Company’s ability to operate successfully in the future, while also prohibiting the Company from conducting important business matters such as : ( 1) increasing the authorized number of shares of common stock , if required for future equity transactions; (2) in its discretion, to effectuate a reverse stock split of the Company’s common stock, at a ratio o

View Full Filing

View this DEFA14A filing on SEC EDGAR